Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease

Launched by TIANJIN MEDICAL UNIVERSITY · Apr 23, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a special imaging test called HED PET/CT to see how effective it is in diagnosing certain diseases related to the sympathetic nervous system, which controls many automatic body functions. The researchers want to find out if this test can help identify both primary tumors (cancer that starts in one area) and metastatic lesions (cancer that has spread from one part of the body to another) in patients who have conditions related to Tau, a protein linked to various diseases.

To participate in this trial, adults aged 18 and older who have suspected or newly diagnosed cancers may be eligible, especially if they have already scheduled an HED PET/CT scan. Participants will need to provide written consent, meaning they agree to join the study after understanding what it involves. Those with non-cancerous growths, pregnant individuals, and those unable or unwilling to give consent will not be able to participate. If you join this study, you'll be contributing to important research that could help improve how we diagnose and treat these conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.